Avecort, ointment 0.1% 15 g

Pharmacodynamics

Mometasone furoate is a synthetic glucocorticosteroid (GCS) for topical use. It has anti-inflammatory, antipruritic and anti-exudative effects.

The GKS induce the release of phospholipase Ai inhibitory proteins, collectively known as lipocortins, which control the biosynthesis of inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid.

Pharmacokinetics

The absorption of the drug Avecort ointment for external use is negligible. Eight hours after application on intact skin (without an occlusive dressing) about 0.7% of the steroid is detected in the systemic bloodstream.

Indications

Insect bites, Dermatitis, Psoriasis, Burns, Diathesis, Eczema, Allergies, DermatosisInflammatory phenomena and itching in glucocorticosteroid-tolerant dermatoses.

Active ingredient

Mometazone

Composition

Per 100 g:

active ingredient:

mometasone furoate – 0.1 g;

excipients:

Vaseline – 77.9 g,

propylene glycol – 12.0 g,

emulsion wax – 5.0 g,

Purified water – 3.0 g,

Glyceryl monostearate – 2.0 g,

Phosphoric acid to pH 3.0-7.5.

How to take, the dosage

Outwardly.

A thin layer of ointment is applied to the affected areas of the skin once a day. The duration of treatment depends on the effectiveness of therapy, as well as the tolerability of the drug by the patient, the presence and severity of side effects.

Interaction

No interaction of the drug Avecort ointment for external use with other drugs has been registered.

Special Instructions

If there is no effect within 2 weeks of therapy with the drug the diagnosis should be clarified.

Any of the side effects described for systemic use of glucocorticosteroids, including suppression of adrenal function, may also occur with local administration, especially in children.

When applied to large areas of skin for a long time, especially when using occlusive dressings, systemic action of GCS may develop. Taking this into account it is necessary to monitor the function of hypothalamic-pituitary-adrenal system. Avoid getting the drug in the eyes.
Propylene glycol contained in the drug may cause irritation at the application site. In such cases the drug should be discontinued and the appropriate treatment should be prescribed.

It should be taken into account that GCS may alter the manifestation of some skin diseases that may hinder in making a diagnosis. In addition, the use of GCS may cause delayed wound healing.

With prolonged therapy with GCS sudden discontinuation of therapy may lead to the development of ricochet syndrome, manifested as dermatitis with intense redness of the skin and burning sensation. Therefore, after a long course of treatment, withdrawal of the drug should be done gradually, e.g. by switching to an intermittent treatment regimen before stopping it completely.

Pediatric use:

Due to the fact that children have a greater surface area to body weight ratio than adults, children are at greater risk of suppression of hypothalamic-pituitary-adrenal system function and development of Icenko-Cushing syndrome when using any topical GCS. Prolonged treatment of children with GCS may result in impairment of their growth and development. The use of the drug in children for more than 3 weeks has not been studied.

Children should receive the minimum dose of the drug, sufficient to achieve the effect.

Influence of the drug Avecort ointment for external use on the ability to drive vehicles and mechanisms

No effect of the drug Avecort ointment for external use on the ability to drive or move machinery has been noted.

Contraindications

• High sensitivity to any component of the drug or to GCS;
• Pink acne, perioral dermatitis;
• Bacterial, viral (herpes virus, varicella) or fungal skin infection;
• Tuberculosis, syphilis;
• Post vaccine reactions.Post-vaccination reactions;
• Pregnancy (application to large areas of skin, prolonged treatment);
• Lactation period (use in high doses or/and for a long time);
• Children under 2 years (due to insufficient data).

With caution

• application to the face and intertriginous skin surface;
• Application of occlusive dressings, as well as application to large areas of skin and/or prolonged treatment (especially in children).
• long-term GCS therapy.

.

Side effects

Classification of the frequency of side effects according to the recommendations of the World Health Organization (WHO): Very common >1/10; common >1/100 to <1/10; infrequent >1/1000 to <1/100; rare >1/10000 to <1/1000; very rare <1/10000, including individual reports; frequency is unknown – it is impossible to determine the incidence from the available data.

Infectious and parasitic diseases:
rarely, folliculitis, secondary infection.

Skin and subcutaneous tissue disorders:

Rarely – skin irritation, dry skin, burning sensation of the skin, itching, hypertrichosis, acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, skin atrophy, stretch marks, sweat, papule and pustule formation.

Nervous system disorders:

Frequency unknown – paresthesias.

When external forms of GCS are used for prolonged periods and/or when applied to large areas of skin, or with the use of occlusive dressings, especially in children and adolescents, side effects characteristic of systemic GCS may occur, including adrenal insufficiency and Itzenko-Cushing’s syndrome.

Overdose

Symptoms: suppression of hypothalamic-pituitary-adrenal system function (including secondary adrenal insufficiency).

Treatment: symptomatic. If necessary – correction of water-electrolyte imbalance, withdrawal of the drug (with prolonged therapy – gradual withdrawal).

Pregnancy use

The safety of using mometasone during pregnancy and lactation has not been studied. GCSs penetrate the placental barrier. Long-term treatment and high doses should be avoided during pregnancy and due to the risk of adverse effects on fetal development.

GCS are excreted with breast milk. In cases where the use of GCS in high doses and/or for a long time is expected, breastfeeding should be stopped.

Similarities

Desrinit spray, Momat Rhino, Nosefrine, Mometazon, Rialtris, Momeid